METHODS OF INDUCING OVULATION
    2.
    发明申请
    METHODS OF INDUCING OVULATION 失效
    诱导卵泡的方法

    公开(公告)号:US20060293222A1

    公开(公告)日:2006-12-28

    申请号:US11456033

    申请日:2006-07-06

    IPC分类号: A61K38/24

    摘要: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.

    摘要翻译: 本发明涉及在雌性宿主中诱导排卵的方法,包括向雌性宿主施用非多肽环状腺苷一磷酸(cAMP)水平调节剂。 另一方面,本发明提供在宿主排卵周期的黄体期之前特异性施用磷酸二酯酶抑制剂。 优选的非多肽cAMP水平调节剂包括磷酸二酯酶抑制剂,特别是磷酸二酯酶4同种型的抑制剂。

    Methods of inducing ovulation
    7.
    发明授权
    Methods of inducing ovulation 失效
    诱导排卵的方法

    公开(公告)号:US07078236B2

    公开(公告)日:2006-07-18

    申请号:US11169183

    申请日:2005-06-28

    IPC分类号: A61K38/24 C12N15/15

    摘要: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.

    摘要翻译: 本发明涉及在雌性宿主中诱导排卵的方法,包括向雌性宿主施用非多肽环状腺苷一磷酸(cAMP)水平调节剂。 另一方面,本发明提供在宿主排卵周期的黄体期之前特异性施用磷酸二酯酶抑制剂。 优选的非多肽cAMP水平调节剂包括磷酸二酯酶抑制剂,特别是磷酸二酯酶4同种型的抑制剂。

    IFNAR2/IFN complex
    10.
    发明授权
    IFNAR2/IFN complex 有权
    IFNAR2 / IFN复合物

    公开(公告)号:US06372207B1

    公开(公告)日:2002-04-16

    申请号:US09215212

    申请日:1998-12-18

    IPC分类号: A61K3821

    摘要: The in vivo effect of Type I interferon (IFN) can be prolonged by administering the interferon in the form of a complex with an IFN binding chain of the human interferon &agr;/&bgr; receptor (IFNAR). Such a complex also improves the stability of the IFN and enhances the potency of the IFN. The complex may be a non-covalent complex or one in which the IFN and the IFNAR are bound by a covalent bond or a peptide. When bound by a peptide bond in the form of a fusion protein, the IFN may be separated from the IFNAR by means of a peptide linker. Such a fusion protein may be produced by recombinant DNA technology. Storing IFN in the form of such a complex improves the storage life of the IFN and permits storage under milder conditions than would otherwise be possible.

    摘要翻译: I型干扰素(IFN)的体内效应可以通过以与人类干扰素α/β受体(IFNAR)的IFN结合链的复合物的形式施用干扰素来延长。 这样的复合物还可以改善IFN的稳定性并提高IFN的效力。 复合物可以是非共价复合物或其中IFN和IFNAR通过共价键或肽结合的复合物。 当以融合蛋白形式的肽键结合时,IFN可以通过肽接头与IFNAR分离。 这种融合蛋白可以通过重组DNA技术产生。 以这种复合物的形式存储IFN可改善IFN的储存期,并允许在比其它条件下更温和的条件下储存。